n,n-dimethylarginine has been researched along with valsartan in 10 studies
| Studies (n,n-dimethylarginine) | Trials (n,n-dimethylarginine) | Recent Studies (post-2010) (n,n-dimethylarginine) | Studies (valsartan) | Trials (valsartan) | Recent Studies (post-2010) (valsartan) |
|---|---|---|---|---|---|
| 2,216 | 228 | 1,221 | 3,577 | 871 | 2,140 |
| Protein | Taxonomy | n,n-dimethylarginine (IC50) | valsartan (IC50) |
|---|---|---|---|
| Type-1A angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0027 | |
| Type-1B angiotensin II receptor | Rattus norvegicus (Norway rat) | 0.0023 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0074 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böger, RH; Maas, R; Quispe-Bravo, S; Schwedhelm, E; Skamira, C | 1 |
| Aslam, S; Leone, A; Santha, T; Wilcox, C | 1 |
| Zoccali, C | 1 |
| Acikel, C; Caglar, K; Cakir, E; Eyileten, T; Kurt, Y; Oguz, Y; Saglam, M; Sonmez, A; Tasar, M; Vural, A; Yenicesu, M; Yilmaz, MI | 1 |
| Koji, Y; Shiina, K; Tomiyama, H; Yamada, J; Yamashina, A; Yoshida, M | 1 |
| Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C | 1 |
| Aydogan, U; Cakir, E; Iyisoy, A; Parlak, A; Saglam, K | 1 |
| Baschiera, F; Botha, J; Brunel, P; Lacy, PS; Prescott, MF; Williams, B | 1 |
| Brown, NJ; Gamboa, JL; Ikizler, TA; Pretorius, M; Sprinkel, KC | 1 |
| Černe, D; Drevenšek, G; France Štiglic, A; Janić, M; Jerin, A; Lunder, M; Marc, J; Šabovič, M; Skitek, M | 1 |
1 review(s) available for n,n-dimethylarginine and valsartan
| Article | Year |
|---|---|
Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Biomarkers; Calcium; Calcium Channel Blockers; Humans; Kidney Failure, Chronic; Risk Factors; Tetrazoles; Valine; Valsartan | 2006 |
6 trial(s) available for n,n-dimethylarginine and valsartan
| Article | Year |
|---|---|
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arginine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Female; Humans; Hypertension, Renal; Kidney Failure, Chronic; Male; Methylation; Middle Aged; Oxidative Stress; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2006 |
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Female; Glomerular Filtration Rate; Hemorheology; Humans; Insulin Resistance; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proteinuria; Ramipril; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2007 |
Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; Endothelium, Vascular; Female; Forearm; Humans; Hyperemia; Hypertension; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.
Topics: Adult; Aged; Amides; Arginine; Blood Pressure; Demography; Endpoint Determination; Exercise; Female; Fumarates; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Renin; Renin-Angiotensin System; Systole; Tetrazoles; Valine; Valsartan | 2013 |
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Bradykinin; Cell Line; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ramipril; Renal Dialysis; Valsartan | 2015 |
3 other study(ies) available for n,n-dimethylarginine and valsartan
| Article | Year |
|---|---|
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Benzimidazoles; Benzoates; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Endothelium, Vascular; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Renal Insufficiency; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Arginine; Benzopyrans; C-Reactive Protein; Ethanolamines; Female; Humans; Hypertension; Male; Middle Aged; Nebivolol; Serum Amyloid P-Component; Tetrazoles; Valine; Valsartan | 2012 |
Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Blood Pressure; Cholesterol; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Rats, Wistar; Receptor, Endothelin A; Time Factors; Valsartan; Vasodilation | 2017 |